Build the ecosystem to advance your scientific mission.
We help founders, CEOs, and leadership teams in health and science create the narrative infrastructure they need to succeed — reaching the right people, in the right way, to secure the funding, partnerships, and policy outcomes their mission depends on.
THE REAL PROBLEM
Those leading scientific enterprises know effective communication earns valuable attention. But attention is fleeting. Without the infrastructure to convert attention into new opportunities, the world moves on.
Even if they land the interview. Even if the op-ed gets published. Even if the keynote earns a standing-room crowd.
Attention isn't impact. Attention doesn't fund the lab, sign the partnership, or change the policy.
The old playbook — corporate PR grafted onto scientific organizations — was never built for this. And the funding model it grew up alongside is gone: the single pipeline that sustained science for decades has fractured, and every scientific leader is now making their case to funders who will never read the journal article. Explaining science better is a tactic. What's needed is infrastructure.
WHAT WE DO
Most scientific organizations communicate. Few convert communication into funding.
We close that gap — not with more content, but with deeper thinking, better placement, and coordinated presence.
We close that gap with narrative infrastructure — an end-to-end system, not more content. One end is insight: we surface what only your organization can say, the through-line inside your science that others flatten into findings. The other end is impact: funding mobilized, partnerships signed, policy changed. In between, we position your leaders for the rooms where those decisions happen — and we support them as whole people, with coaching and stress resilience for the visibility those rooms demand. Scientists are too often treated as cogs in their own enterprise. Not here.
This is Science Relations: communication not as a support function or a silo, but as how you advance the science, the mission, and the balance sheet.
From insight to impact
We don’t sell communications. We sell what communications makes possible.
A sample of the record:
$48.6M → $131M
270% funding increase from PEPFAR
TB is the leading killer of people with HIV, yet PEPFAR wasn’t routinely funding integrated TB-HIV services. We synthesized the co-infection research, showed where programming failed the epidemiology, and built relationships inside PEPFAR — with Congressional allies and Archbishop Desmond Tutu providing outside leverage.
The TB-HIV budget line grew 270% in one year. An independent evaluation confirmed the white paper was instrumental.
“It was instrumental to the advocacy that got the addition to PEPFAR funds.” — PEPFAR official
A co-epidemic, funded
TB-diabetes on the global agenda
Research linked TB and diabetes, but only small academic circles noticed. Working with The Union and the International Diabetes Federation, we turned the evidence into a white paper and a media moment — CNN, Financial Times, Reuters — that made the co-epidemic impossible to ignore.
Partners stepped forward to fund the first global TB-diabetes summit; delegates signed the Bali Declaration; India built a national policy framework naming The Union as instrumental.
7.5M children
UN targets for childhood TB
Children with TB had been neglected for decades. We produced the white paper, launched it at the World Health Assembly ahead of the 2018 UN High-Level Meeting, and ran the advocacy: UN missions, parliamentarians, journalist delegations, coalition work with WHO and UNICEF.
The UN General Assembly endorsed targets to treat 3.5 million children and prevent TB in 4 million — targets now driving national budgets in high-burden countries.
These outcomes weren’t produced by press releases. Each began with an insight buried in research, built into infrastructure, and carried through to money moved and policy made. That’s the system we build for scientific organizations.
OUR TRACK RECORD
Our co-founders have shaped thought leadership and storytelling narratives for C-suite executives of publicly traded companies surpassing $500B in market cap, multilateral institutions with budgets surpassing $10B, and research universities with endowments surpassing $100B — across dozens of countries, over a combined 38 years.
Every health and science op-ed we've committed to in the past decade has been published.
Wall Street Journal · New York Times · Financial Times · STAT · Nature Reviews Cardiology · and 30+ more — for authors from staff scientists to heads of state.
Before your next funder enters the room, they'll search for you. Op-eds are what they should find.
WHO WE WORK WITH
We work with leadership teams that feel a deep purpose in their work and are striving to accomplish big things. We're not the right fit for organizations that are so established they've stopped feeling the need to prove themselves. Most come to us at an inflection point: a raise, a diversification mandate, a policy window, a mission bigger than its current budget.
OUR IDEAL CLIENTS ARE AT LEAST SLIGHTLY INTIMIDATED BY THE SIZE OF THEIR VISION.
THIS IS WHERE IT STARTS
In a generation, science hasn't faced a more urgent need to build differently.
The funding playbook that carried your field for decades is being rewritten in real time. If you're ready to explore what narrative infrastructure looks like for your organization —